Barclays
ACRV icon

Barclays’s Acrivon Therapeutics ACRV Stock Holding History

Barclays’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Buy
7,354
+1,414
+24% +$2.4K ﹤0.01% 4664
2026
Q1 		$8.26K Sell
5,940
-18,462
-76% -$32.2K ﹤0.01% 4725
2025
Q4 		$58.8K Buy
24,402
+4,437
+22% +$9.64K ﹤0.01% 4713
2025
Q3 		$36.1K Sell
19,965
-960
-5% -$1.35K ﹤0.01% 4846
2025
Q2 		$24.9K Sell
20,925
-11,773
-36% -$16.2K ﹤0.01% 4816
2025
Q1 		$66.4K Sell
32,698
-5,393
-14% -$29K ﹤0.01% 4533
2024
Q4 		$229K Buy
38,091
+4,785
+14% +$34.8K ﹤0.01% 4243
2024
Q3 		$233K Buy
33,306
+11,273
+51% +$88.8K ﹤0.01% 4219
2024
Q2 		$128K Buy
22,033
+709
+3% +$5.71K ﹤0.01% 3790
2024
Q1 		$152K Sell
21,324
-3,160
-13% -$14.7K ﹤0.01% 4248
2023
Q4 		$120K Buy
24,484
+10,384
+74% +$54.8K ﹤0.01% 4593
2023
Q3 		$135K Sell
14,100
-163
-1% -$1.88K ﹤0.01% 3476
2023
Q2 		$185K Sell
14,263
-2,720
-16% -$32.9K ﹤0.01% 3283
2023
Q1 		$216K Buy
16,983
+12,841
+310% +$216K ﹤0.01% 3745
2022
Q4 		$47.7K Buy
+4,142
New +$52.6K ﹤0.01% 4569

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's ACRV Position: Q2 2026 in Review

Barclays increased its Acrivon Therapeutics (ACRV) stake by 24% in Q2 2026, buying an estimated $2.4K and bringing the position to 7,354 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4664.

Barclays first reported a position in ACRV in Q4 2022 and has held it in 15 quarters since. The position peaked at $233K in Q3 2024. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Barclays held 7,354 shares of Acrivon Therapeutics worth $13.1K as of Q2 2026.
  • Barclays bought 1,414 Acrivon Therapeutics shares in Q2 2026, an estimated $2.4K.
  • Acrivon Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4664 holding.
  • Barclays first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Barclays's Acrivon Therapeutics position peaked at $233K in Q3 2024.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.